In this study, E.coli Nissle 1917 (EcN), an intestinal probiotic, was utilized as a targeted transport vector to deliver p53 and Tum-5 protein to tumor hypoxic regions. The tumor-targeting characteristics of EcN were investigated using luciferase Lux CDABE operon, and the results demonstrated that EcN could specifically accumulate in the solid Probiotic microorganisms have been defined as live microbes that, when administered in adequate amounts, confer a health benefit on the host [4, 5]. A particularly well-investigated probiotic strain is Escherichia coli Nissle 1917 (serotype O6:K5:H1) (EcN). Escherichia coli Nissle 1917 (EcN) is a probiotic bacterium, commonly employed to treat certain gastrointestinal disorders. It is fast emerging as an important target for the development of therapeutic engineered bacteria, benefiting from the wealth of knowledge of E. coli biology and ease of manipulation. Bacterial synthetic biology projects commonly utilize engineered plasmid vectors, which E. coli jako probiotyk. Szczep E. coli Nissle 1917 ma zastosowanie jako probiotyk. Wykazano, że przyjmowanie preparatów z tym szczepem bakterii jest skuteczne w podtrzymywaniu remisji wśród chorych na wrzodziejące zapalenie jelita grubego. Niestety nie udowodniono takiego działania w chorobie Leśniowskiego-Crohna. Characteristics of E. coli Nissle 1917. Escherichia coli Nissle 1917 (EcN) is a Gram‐negative probiotic, originally isolated by Dr. Alfred Nissle during World War I (Nissle, 1918; Nissle, 1925).EcN is serum‐sensitive and does not produce any enterotoxins or cytotoxins associated with pathogenic E. coli strains (Sonnenborn and Schulze, 2009).It has been licensed as a pharmaceutical for the The authors engineered a probiotic based on Escherichia coli Nissle 1917 that non-invasively monitors and records gut inflammation in real time, and releases a therapeutic. These bacteria that the .

e coli nissle 1917 probiotic